Results 111 to 120 of about 4,608 (197)

Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes – [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience – do we need [18F]FDG

, 2020
Anna Zemczak, Maciej Kołodziej, Paweł Gut, Leszek Królicki, Beata Kos‐Kudła, Grzegorz Kamiński, Marek Ruchała, Dariusz Pawlak, Jolanta Kunikowska   +8 more
openalex   +2 more sources

Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study [PDF]

Rachele Danieli, Magdalena Mileva, Gwennaëlle Marin, Paulus Kristanto, Wendy Delbart, Bruno Vanderlinden, Zéna Wimana, Alain Hendlisz, Hugo Levillain, N. Reynaert, Patrick Flamen, Ioannis Karfis   +11 more
openalex   +1 more source

Mutations in PRRT2 are not a common cause of infantile epileptic encephalopathies [PDF]

, 2013
Sarah E. Heron, Yeh Sze Ong, Simone C. Yendle, Jacinta M. McMahon, Samuel F. Berkovic, Ingrid E. Scheffer, Leanne M. Dibbens   +6 more
openalex   +1 more source

Estimation of kidney doses from [177Lu]Lu-DOTA-TATE PRRT using single time point post-treatment SPECT/CT [PDF]

Safia Spink, Daniel Gillett, Sarah Heard, Inês Harper, Ruth Casey, Luigi Aloj   +5 more
openalex   +1 more source

Safety and efficacy of peptide receptor radionuclide therapy for advanced medullary thyroid cancer: a systematic review and meta-analysis. [PDF]

Thyroid Res
Abdlkadir AS, Al-Adhami D, Shi H, Sathekge MM, Sheikha AA, Mohamad I, Kreissl M, Al-Ibraheem A.   +7 more
europepmc   +1 more source

Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients. [PDF]

Curr Treat Options Oncol
Mohindroo C, Ramirez RA.
europepmc   +1 more source

Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years. [PDF]

Theranostics
Zhang J, Mensel B, Baum RP.
europepmc   +1 more source

A Retrospective Analysis of Lutetium-177 PRRT in Patients with Metastatic Neuroendocrine Tumors: Study to Guide Dose Reduction from 200 to 100 mCi per Cycle of Lu-177 DOTATATE Therapy

Y. S. Manikya, Nandini Pandit, Brinda Ravichandran, S. J. Seetharam, Vishnu Kumar, Pradap Velu, Sathya Narayanan, Srinivas Ananth Kumar, Harish Goyal, Dhanapathi Halanaik   +9 more
openalex   +1 more source

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

, 2023
Çağlar Ünal
openalex   +1 more source

Radioligand Therapy in Meningiomas: Today's Evidence, Tomorrow's Possibilities. [PDF]

Cancers (Basel)
Sipka G, Apro K, Farkas I, Bakos A, Dobi A, Hideghety K, Pavics L, Dosa S, Radics B, Balazsfi M, Barzo P, Szolikova M, Besenyi Z.   +12 more
europepmc   +1 more source